Ultragenyx Gene Therapy Hits Phase 3 Endpoint; Lilly's $3B China Bet; LAG-3 Oncology Setback

Ultragenyx's gene therapy clears pivotal trial for raremetabolic disease — a critical win for the gene therapy sector. Lilly invests $3B in China manufacturing for oral GLP-1 and escalates the compounding fight. LAG-3 pioneer fails Phase 3, raising hard questions about the immuno-oncology target. Plus: GSK Arexvy wins expanded RSV approval.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Ultragenyx, #genetherapy, #urea cycle disorder, #Eli Lilly, #orforglipron, #GLP-1, #tirzepatide,#compounding pharmacies, #LAG-3, #immuno-oncology, #checkpoint inhibitor, #GSK,#Arexvy, #RSV vaccine, #rare disease, #orphan drugs, #Pfizer, #Lilly, #Roche